AstraZeneca Enters Deal to Distribute Sun Pharma Cancer Drugs in China

Sun Pharma has entered into a licensing agreement with AstraZeneca UK to introduce certain novel ready-to-use infusion oncology products in China.

Under the deal, Sun Pharma will be responsible for development, regulatory filings and manufacturing the products covered in the agreement while AstraZeneca will exclusively promote and distribute the products.

The initial duration of the agreement will be 10 years from the first commercial sale of the products in China.